CMBL Inhibitors
CMBL inhibitors, or carboxymethylenebutenolidase inhibitors, belong to a class of chemical compounds designed to modulate the activity of the carboxymethylenebutenolidase enzyme, also known as CMBL. The carboxymethylenebutenolidase enzyme plays a crucial role in various biochemical processes within the human body, particularly in the metabolism of xenobiotics, drugs, and certain endogenous substrates. CMBL is a serine hydrolase enzyme found in various tissues and organs, with notable expression in the liver and kidney.
The primary function of CMBL is its involvement in the hydrolysis of carboxymethylenebutenolidase substrates, which include compounds like prodrugs and endogenous molecules. These substrates are often inactive or less bioavailable in their native form and require enzymatic conversion by CMBL to become pharmacologically active or more readily absorbed by the body. Consequently, CMBL inhibitors are designed to interfere with this enzymatic activity, either by binding to the enzyme's active site or by modulating its expression, leading to a reduction in substrate hydrolysis. By inhibiting CMBL, these compounds can impact the bioavailability and pharmacokinetics of various drugs and xenobiotics, affecting their efficacy and safety profiles.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib is a tyrosine kinase inhibitor that targets the BCR-ABL fusion protein, inhibiting its activity and blocking the phosphorylation of downstream signaling molecules, thereby inhibiting cell proliferation in chronic myeloid leukemia. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib is a multi-kinase inhibitor that targets RAF kinases and VEGFR, reducing angiogenesis and inhibiting cell growth in various cancers, including hepatocellular carcinoma. | ||||||
Tamoxifen | 10540-29-1 | sc-208414 | 2.5 g | $272.00 | 18 | |
Tamoxifen is a selective estrogen receptor modulator (SERM) that competes with estrogen for binding to estrogen receptors in breast tissue, thereby blocking estrogen's effects and inhibiting the growth of estrogen receptor-positive breast cancer cells. | ||||||
MDV3100 | 915087-33-1 | sc-364354 sc-364354A | 5 mg 50 mg | $245.00 $1051.00 | 7 | |
Enzalutamide is an androgen receptor inhibitor that binds to the androgen receptor, blocking its translocation to the nucleus and inhibiting the transcription of genes involved in prostate cancer growth. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Erlotinib is an epidermal growth factor receptor (EGFR) inhibitor that competes with ATP for binding to the EGFR kinase domain, blocking downstream signaling pathways and inhibiting cell proliferation in lung and pancreatic cancers. | ||||||
Everolimus | 159351-69-6 | sc-218452 sc-218452A | 5 mg 50 mg | $131.00 $651.00 | 7 | |
Everolimus is an mTOR inhibitor that blocks the mTOR pathway, reducing protein synthesis and inhibiting cell proliferation in various cancers, including advanced renal cell carcinoma and pancreatic neuroendocrine tumors. | ||||||
ABT-199 | 1257044-40-8 | sc-472284 sc-472284A sc-472284B sc-472284C sc-472284D | 1 mg 5 mg 10 mg 100 mg 3 g | $118.00 $337.00 $520.00 $832.00 $1632.00 | 10 | |
Venetoclax is a BCL-2 inhibitor that binds to the anti-apoptotic protein BCL-2, disrupting its function and promoting apoptosis in chronic lymphocytic leukemia cells that overexpress BCL-2. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a multi-kinase inhibitor that targets BCR-ABL, Src family kinases, and others, inhibiting the proliferation of cells in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. | ||||||
Olaparib | 763113-22-0 | sc-302017 sc-302017A sc-302017B | 250 mg 500 mg 1 g | $210.00 $305.00 $495.00 | 10 | |
Olaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor that traps PARP enzymes at DNA damage sites, blocking DNA repair in BRCA-mutated cancer cells and leading to their selective death. | ||||||
Abemaciclib | 1231929-97-7 | sc-507342 | 10 mg | $110.00 | ||
Abemaciclib is a cyclin-dependent kinase (CDK) 4 and 6 inhibitor that blocks cell cycle progression by inhibiting the activity of CDK4 and CDK6, leading to cell cycle arrest and reduced proliferation in breast cancer. | ||||||